Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISA...

Descripción completa

Detalles Bibliográficos
Autores principales: Jääskeläinen, Anne J, Kekäläinen, Eliisa, Kallio-Kokko, Hannimari, Mannonen, Laura, Kortela, Elisa, Vapalahti, Olli, Kurkela, Satu, Lappalainen, Maija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219034/
https://www.ncbi.nlm.nih.gov/pubmed/32400364
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.18.2000603
_version_ 1783532914720374784
author Jääskeläinen, Anne J
Kekäläinen, Eliisa
Kallio-Kokko, Hannimari
Mannonen, Laura
Kortela, Elisa
Vapalahti, Olli
Kurkela, Satu
Lappalainen, Maija
author_facet Jääskeläinen, Anne J
Kekäläinen, Eliisa
Kallio-Kokko, Hannimari
Mannonen, Laura
Kortela, Elisa
Vapalahti, Olli
Kurkela, Satu
Lappalainen, Maija
author_sort Jääskeläinen, Anne J
collection PubMed
description Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.
format Online
Article
Text
id pubmed-7219034
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-72190342020-05-15 Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples Jääskeläinen, Anne J Kekäläinen, Eliisa Kallio-Kokko, Hannimari Mannonen, Laura Kortela, Elisa Vapalahti, Olli Kurkela, Satu Lappalainen, Maija Euro Surveill Rapid Communication Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset. European Centre for Disease Prevention and Control (ECDC) 2020-05-07 /pmc/articles/PMC7219034/ /pubmed/32400364 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.18.2000603 Text en This article is copyright of the authors or their affiliated institutions, 2020. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Jääskeläinen, Anne J
Kekäläinen, Eliisa
Kallio-Kokko, Hannimari
Mannonen, Laura
Kortela, Elisa
Vapalahti, Olli
Kurkela, Satu
Lappalainen, Maija
Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples
title Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples
title_full Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples
title_fullStr Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples
title_full_unstemmed Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples
title_short Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples
title_sort evaluation of commercial and automated sars-cov-2 igg and iga elisas using coronavirus disease (covid-19) patient samples
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219034/
https://www.ncbi.nlm.nih.gov/pubmed/32400364
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.18.2000603
work_keys_str_mv AT jaaskelainenannej evaluationofcommercialandautomatedsarscov2iggandigaelisasusingcoronavirusdiseasecovid19patientsamples
AT kekalaineneliisa evaluationofcommercialandautomatedsarscov2iggandigaelisasusingcoronavirusdiseasecovid19patientsamples
AT kalliokokkohannimari evaluationofcommercialandautomatedsarscov2iggandigaelisasusingcoronavirusdiseasecovid19patientsamples
AT mannonenlaura evaluationofcommercialandautomatedsarscov2iggandigaelisasusingcoronavirusdiseasecovid19patientsamples
AT kortelaelisa evaluationofcommercialandautomatedsarscov2iggandigaelisasusingcoronavirusdiseasecovid19patientsamples
AT vapalahtiolli evaluationofcommercialandautomatedsarscov2iggandigaelisasusingcoronavirusdiseasecovid19patientsamples
AT kurkelasatu evaluationofcommercialandautomatedsarscov2iggandigaelisasusingcoronavirusdiseasecovid19patientsamples
AT lappalainenmaija evaluationofcommercialandautomatedsarscov2iggandigaelisasusingcoronavirusdiseasecovid19patientsamples

Ejemplares similares